News
Kamada to begin advanced-phase clinical trials in Europe of inhalable Alpha-1 treatment
Globes online
Israeli drug developer Kamada Ltd. is beginning the Phase II/III clinical trial in Europe of inhalable alpha-1 antitrypsin (AAT) for the treatment of hereditary chronic obstructive pulmonary disease, or “genetic COPD”. The trial will begin at sites in the Netherlands during the fourth quarter of 2009.
The European Medicines Agency (EMEA) and the Dutch Central Committee on Research Involving Human Subjects (CCMO) has approved the trial protocol.
AAT is Kamada’s flagship product. The Phase III trial for intravenous AAT in the US has been successful, and the company is waiting for marketing certification of the drug from the US Food and Drug Administration (FDA).
Kamada’s intravenous augmentation product would be the fourth available in the United States.
Kamada is planning a bond offering, convertible to shares at NIS 35. Kamada’s share rose 1.8% at the opening today to NIS 29.70, giving a market cap of NIS 665 million.
